REG is an oral multi-kinase inhibitor targeting VEGFR-1,−2,−3, tyrosine kinase with Ig and EGF (TIE2), platelet-derived growth factor receptors (PDGFR), Fibroblast growth factor receptors (FGFR), proto-oncogene receptor tyrosine kinase (KIT), Raf-1 Proto-Oncogene, Serine/Threonine Kinase (RAF-1), rearranged during transfection (RET), and BRAF, investigated in the randomized phase II trial Regorafenib in Relapsed Glioblastoma (REGOMA) and approved for the management of recurrent GB by the European Medicines Agency. This evidence concerns the gene RAF1 and glioblastoma.